study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
INFL-INF10-01,2014,randomized controlled trial,SMD,-0.3724,-0.5378,-0.207,82,82,low,10.1234/infl-inf10-01,inflammation-journal-01,skin_inflammation,Adults with skin inflammation concerns,Mild GI discomfort,10
INFL-INF10-02,2019,randomized controlled trial,SMD,-0.367,-0.5148,-0.2192,95,97,some concerns,10.1234/infl-inf10-02,inflammation-journal-02,skin_inflammation,Adults with skin inflammation concerns,Mild GI discomfort,9
INFL-INF10-03,2010,randomized controlled trial,SMD,-0.3616,-0.4918,-0.2314,78,82,some concerns,10.1234/infl-inf10-03,inflammation-journal-03,skin_inflammation,Adults with skin inflammation concerns,None reported,13
